Consolidated Financial Highlights

Particulars

Q1

FY24

Q1

FY23

YoY Growth

Q4

FY23

QoQ Growth

Revenue from Operation

1,749

1,482

18 %

2,164

-19 %

   CDMO

898

770

17 %

1,285

-30 %

   Complex Hospital Generic (CHG)

617

508

22 %

702

-12 %

   India Consumer Healthcare (ICH)

239

211

13 %

206

16 %

EBITDA

171

89^#

92 %

376

-55 %

EBITDA Margin

10 %

6 %

17 %

PAT

-99

-109

NA

50

-297 %

PAT Margin

-6 %

-7 %

2 %

Key Business Highlights for Q1FY24

Contract Development and Manufacturing Organization (CDMO):

• Witnessed continued order inflow momentum and strong execution in Q1FY24. Continue to see good demand for our differentiated offering in the niche areas of high potent API, peptide, anti-body drug conjugate (ADC) and development and manufacturing of on-patent API
• Recently expanded capacities at sites with differentiated offering witnessing encouraging customer demand
• Capacity expansion for antibody drug conjugate (ADC) at Grangemouth facility to strengthen our position in the ADC market
• YoY improvement in demand for our generic API business
• Maintained our quality track record – Successfully cleared 8 regulatory inspections (including an US FDA inspection at our Pithampur facility) and multiple customer audits in Q1FY24
• Cost optimization, strategizing procurement and operational excellence initiatives helping to mitigate inflationary pressures and improve profitability

Complex Hospital Generics (CHG):

• Continued momentum in Inhalation Anesthesia (IA) sales, mainly led by strong demand for Sevoflurane
• Expanding inhalation anesthesia capacity to meet the growing demand
• Intrathecal portfolio in the US continue to command leading market share
• Building a pipeline of 27+ new products which are various stages of development. Launched 1 new product during Q1FY24
• Appointed Jeffrey Hampton as President & Chief Operating Officer of CHG Business. Jeff has previously worked with Accord Healthcare, Inc. and Apotex Inc.  

India Consumer Healthcare (ICH):

• 11 new products and 3 new SKUs launched during Q1FY24
• Continue to invest in media and trade spends to drive growth in power brands
• Power Brands – Littles, Lacto Calamine, Polycrol, Tetmosol and I-range, grew by 15% YoY in Q1FY24 and contribute to 43% of ICH sales
• E-commerce grew by more than 18% YoY in Q1FY24
• Wide distribution reach across general trade and are also strengthening our presence in alternate channels of distribution including e-commerce, modern trade, and having our own direct-to-customer website -Wellify.in

Consolidated Profit and Loss Statement

Reported Financials

Particulars

Q1FY24

Q1FY23

YoY  Change

Q4FY22

QoQ  Change

Revenue from Operations

1,749

1,482

18 %

2,164

-19 %

Other Income

38

72

-47 %

25

56 %

Total Income

1,787

1,554

15 %

2,188

-18 %

Material Cost

627

574

9 %

840

-25 %

Employee Expenses

496

461

8 %

474

5 %

Other Expenses

494

430

15 %

499

-1 %

EBITDA

171

89^#

92 %

376

-55 %

Finance Cost

119

62

90 %

104

14 %

Depreciation

174

162

7 %

184

-6 %

Share of net profit of associates

14

20

-28 %

8

85 %

Profit Before Tax

-107

-115

-7 %

95

-213 %

Tax

-9

-6

NA

45

-119 %

Net Profit after Tax

-99

-109

NA

50

-297 %

Exceptional item

0

0

0

Net Profit after Tax after exceptional item

-99

-109

NA

50

-297 %

Event

Location & Time

Telephone Number

Conference call on
4^th August, 2023

India – 10:00 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 12:30 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 5:30 AM

(London Time)

Toll free number

08081011573

Singapore – 12:30 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:30 PM

(Hong Kong Time)

Toll free number

800964448

Please use this link for prior registration to reduce wait time at the time of joining the call –https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9503078&linkSecurityString=33aa158d84